Integration of meningococcal conjugate vaccination
View Patent ↗Conjugated meningococcal capsular saccharides will be introduced into immunization schedules in the near future, but the phenomenon of “carrier suppression” must first be addressed, particularly where multiple conjugates are to be used. It has been found that diphtheria toxoid and its derivatives (such as CRM197) can safely be used as the carrier protein, even where multiple meningococcal conjugates are administered at the same time and where a patient has previously been exposed to the carrier protein, either in the form of a previous immunogen (e.g. in a DTP vaccine) or as a previous carrier protein (e.g. in a Hib or pneumococcal conjugate vaccine). The invention provides a method for immunizing a patient, comprising administering multiple conjugates of meningococcal capsular saccharides, wherein each conjugate comprises a diphtheria toxoid (or derivative thereof) carrier protein, and the capsular saccharide, and wherein the patient has been pre-immunized with a diphtheria toxoid (or derivative thereof).
1. A method of immunising a human patient against Neisseria meningitides , comprising the step of administering to the human patient a composition that comprises at least two of (a) a conjugate of (i) the capsular saccharide of serogroup A N. meningitidis and (ii) a diphtheria toxoid carrier or CRM197 carrier; (b) a conjugate of (i) the capsular saccharide of serogroup C N. meningitidis and (ii) a diphtheria toxoid or CRM197 carrier; (c) a conjugate of (i) the capsular saccharide of serogroup W135 N. meningitidis and (ii) a diphtheria toxoid or CRM197 carrier; and (d) a conjugate of (i) the capsular saccharide of serogroup Y N. meningitidis and (ii) a diphtheria toxoid or CRM197 carrier, wherein the patient has been pre-immunised with a vaccine comprising (x) a non-conjugated diphtheria toxoid and (z) a conjugate of (i) a capsular saccharide of an organism other than N. meningitidis and (ii) a diphtheria toxoid or CRM197 carrier, wherein the patient was pre-immunised at least six months before the immunization with the N. meningitidis conjugates.
2. The method of claim 1 , wherein the composition comprises all four of (a), (b), (c) and (d).
3. The method of claim 1 , wherein the organism other than the N. meningitidis is Haemophilus influenzae type B.
4. The method of claim 1 , wherein the patient has been pre-immunised with a pneumococcal capsular saccharide conjugated to a diphtheria toxoid or CRM197 carrier.
5. The method claim 1 , wherein the patient was pre-immunised at least eight years before the method of immunization.
6. The method of claim 1 , wherein the pre-immunisation took place within one year of the patient's birth.
7. The method of claim 1 , wherein the saccharides in the conjugates (a) to (d) are shorter than the native capsular saccharides of the corresponding serogroups of N. meningitides.
8. The method of claim 1 , wherein the conjugates (a) to (d) comprise the diphtheria toxoid carrier and an adipic acid linker.
9. The method of claim 8 , wherein the composition comprises no more than 60 microgram of the diphtheria toxoid carriers.
10. The method of claim 1 , wherein the conjugates (a) to (d) comprise the CRM197 carrier and an adipic acid linker.
11. The method of claim 1 , wherein the composition further comprises a conjugated capsular saccharide from Streptococcus pneumoniae.
12. The method of claim 1 , wherein the composition further comprises a conjugated capsular saccharide from Haemophilus influenzae type B.
13. The method of claim 1 , wherein the composition further comprises a protein antigen from serogroup B of Neisseria meningitides.
14. The method of claim 1 , wherein the composition includes an aluminium hydroxide adjuvant and/or an aluminium phosphate adjuvant.
15. The method of claim 2 , wherein the patient has been pre-immunised with a vaccine comprising (x) and (z).
16. The method of claim 2 , wherein the organism other than the N. meningitidis is Haemophilus influenzae type B.
17. The method of claim 2 , wherein the patient has been pre-immunised with a pneumococcal capsular saccharide conjugated to a diphtheria toxoid or CRM197 carrier.
18. The method claim 2 , wherein the patient was pre-immunised at least eight years before the method of immunization.
19. The method of claim 2 , wherein the pre-immunisation took place within one year of the patient's birth.
20. The method of claim 2 , wherein the saccharides in the conjugates (a) to (d) are shorter than the native capsular saccharides of the corresponding serogroups of N. meningitides.
21. The method of claim 2 , wherein the conjugates (a) to (d) comprise the diphtheria toxoid carrier and an adipic acid linker.
22. The method of claim 19 , wherein the composition comprises no more than 60 microgram of the diphtheria toxoid carriers.
23. The method of claim 2 , wherein the conjugates (a) to (d) comprise the CRM197 carrier and an adipic acid linker.
24. The method of claim 2 , wherein the composition further comprises a conjugated capsular saccharide from Streptococcus pneumoniae .
25. The method of claim 2 , wherein the composition further comprises a conjugated capsular saccharide from Haemophilus influenzae type B.
26. The method of claim 2 , wherein the composition further comprises a protein antigen from serogroup B of Neisseria meningitides.
27. The method of claim 2 , wherein the composition includes an aluminium hydroxide adjuvant and/or an aluminium phosphate adjuvant.